Are these ASX 200 'moat' stocks undervalued right now?

Hold the fort! These economic moat companies could protect your investment castle from competitors. 

| More on:
Three boys dressed as knights wield swords as they defend their castle wall.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One strategy investors may consider is buying S&P/ASX 200 Index (ASX: XJO) stocks in companies that have a wide economic 'moat'. 

An economic moat refers to a company's ability to maintain an advantage over competitors. 

A helpful metaphor for understanding this concept is imagining a company as a castle. The body of water (or moat) surrounding it is the advantage that protects the castle (or company) from competitors challenging its position in the market. 

The competitive advantages the company holds over the market could be aspects like:

  • Low-cost production
  • Brand recognition
  • Intellectual property
  • High switching costs
  • Intangible assets

There are several ASX shares that benefit from having a moat.

Here are two that investors looking to add economic 'moat' stocks to their portfolios might consider. 

Cochlear Ltd (ASX: COH)

Cochlear is a medical device company that specialises in designing, developing and manufacturing hearing implants and solutions. 

Its economic moat is largely due to the 500 patents and trademarks on its products.

Cochlear's reputation for producing high-quality and reliable products and its extensive global distribution network also contribute to its moat.

This ASX200 stock has had modest growth over the past 12 months, rising 5.32%. This is largely in line with the healthcare sector as a whole over this time. 

The company is trading well below its 52-week high of $350.31, although it has gotten off to a red-hot start in 2025, rising more than 7% since January 1.

This could be influenced by its new CFO, Sarah Thom, who began her new role this year. 

Bell Potter has a hold rating on the ASX share, suggesting it is close to fair value. 

However, Coclear's long-term aim for annual revenue growth of around 10% coupled with its core hearing implant business, gives it a competitive advantage in the market. 

CSL Ltd (ASX: CSL)

CSL is a leading global biotechnology company. Its three key areas of focus are influenza vaccines and rare and serious diseases. 

Its economic moat is influenced by its intellectual property. CSL has more than 1,500 patents and trademarks in an industry with high barriers to entry for new competitors. 

It is a blue-chip share trading below fair value, according to experts. 

Over the last 12 months, this ASX200 stock has fallen 7.09%. 

Bell Potter has a buy rating and a $345.00 price target on the company's shares. This implies a potential upside of 27% for investors over the next 12 months.

Similarly, Goldman Sachs has a buy rating and a $325.40 price target on CSL's shares. This implies a potential upside of 19% for investors over the next 12 months.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Investing Strategies

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

2 high-quality ASX 200 blue chip shares to buy and hold in February

Analysts are expecting great returns from these buy-rated blue chips.

Read more »

Woman calculating dividends on calculator and working on a laptop.
ETFs

Here's how much the Vanguard MSCI Index International Shares ETF (VGS) currently pays in dividends

The yield on this ETF might surprise you.

Read more »

Warren Buffett
Investing Strategies

Is it smart to buy stocks with the S&P 500 near its record high? Warren Buffett has brilliant advice for investors

The S&P 500 is trading close to its record high, and Wall Street thinks the index is headed higher in…

Read more »

Excited couple celebrating success while looking at smartphone.
Dividend Investing

These top ASX dividend shares could rise 15% to 30%

Analysts expect big things from these dividend payers this year.

Read more »

Two mature-age people, a man and a woman, jump in unison with their arms and legs outstretched on a sunny beach.
Energy Shares

Dividend investors: 2 top ASX energy shares for February

Energy shares an be a great source of passive income...

Read more »

Man putting in a coin in a coin jar with piles of coins next to it.
Dividend Investing

Buy these ASX dividend stocks for a passive income boost

Analysts are bullish on these names. Let's see what they are saying about them.

Read more »

Australian notes and coins symbolising dividends.
Dividend Investing

4 ASX 300 shares with ex-dividend dates before this week ends

You'd better be quick if you want to bag these dividends.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Dividend Investing

5%+ dividend yield: 2 ASX income shares to buy in February

Bell Potter has good things to say about these income options.

Read more »